New hope for tough blood cancers? early trial of JNJ-89853413 begins
NCT ID NCT06618001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called JNJ-89853413 in 64 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, with a second part looking at whether it helps fight the cancer. It's a first-in-human study, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-89853413
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat blood cancers like AML or MDS.
What could go wrong
This is a very early Phase 1 trial with only 64 participants, so safety and dosing are still being figured out. It may not work or could have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrookes Hospital
Cambridge, Cb2 2qq, United Kingdom
-
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2C1, Canada
-
The Christie NHS Foundation Trust Christie Hospital
Manchester, M20 4BX, United Kingdom
-
University College London Hospitals
London, W1T 7HA, United Kingdom
-
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9, Canada